Home
About
Pipeline
Capabilities
News
Contact Us

260652453_4972739792759928_3107566916086768004_n

By Paddy Ryan / December 6, 2021

Post navigation

← Previous Media

Search for:

Recent Posts

Nutriband to Attend 2023 BIO International Convention
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

Its our goal to improve patient comfort, safety and efficacy while setting new safety standards for notoriously abused, yet extremely effective medications!

Linkedin Twitter Facebook

Quick Links

Home
About Us
Our Pipeline
Capabilities
4P Therapeutics
Pocono Pharma

Company Info

NTRB Filings
NTRB Stock Info
NTRB Investor Info
Management Team
Latest Press Releases
Privacy and Cookies Policy
NTRB and GDPR

Contact Info

Nutriband Pharma
121 S. Orange Ave.,
Suite 1500,
Orlando,
FL 32801
[email protected]

Powered by Trigger Media